Hematological toxicities; Post-CAR-T; Post-CAR-T cells; Recommandations; Recommendations; SFGM-TC; Toxicités hématologiques; Receptors, Chimeric Antigen; Humans; France; Neoplasms/therapy; Neutropenia/chemically induced; Neutropenia/therapy; Thrombocytopenia/chemically induced; Thrombocytopenia/therapy; Review Literature as Topic; Hematologic Diseases/therapy; Hematologic Diseases/chemically induced; Immunotherapy, Adoptive/adverse effects; Receptors, Chimeric Antigen/therapeutic use; Societies, Medical/standards; Hematologic Diseases; Immunotherapy, Adoptive; Neoplasms; Neutropenia; Societies, Medical; Thrombocytopenia; Hematology; Oncology; Radiology, Nuclear Medicine and Imaging; Cancer Research
Abstract :
[en] Chimeric antigen receptor T cell (CAR-T cell) therapy has become a standard-of-care for several hematological and a promising treatment for solid malignancies or for selected non-malignant autoimmune disorders. Hematological complications following this treatment are very common with the majority of patients experiencing at least one cytopenia after CAR-T cell injections. The management of these adverse events is not standardized and represents an area of active research and unmet clinical needs. This harmonization workshop, gathering a group of experts who analyzed this topic, has been conceived for the optimization of the management of patients presenting with post-CAR-T cell hematological toxicities. Based on the data present in the literature, these practical recommendations were made to harmonize the practices of Francophone centers involved in the management of these patients.
Disciplines :
Hematology
Author, co-author :
Alsuliman, Tamim; Service d'hématologie et de thérapie cellulaire, hôpital Saint-Antoine, AP-HP Sorbonne université, 184, Faubourg-Saint-Antoine, 75012 Paris, France. Electronic address: Dr.tameemsoliman@gmail.com
Bay, Jacques Olivier; Service de thérapie cellulaire et d'hématologie clinique adulte, CHU de Clermont-Ferrand, Clermont-Ferrand, France. Electronic address: jobay@chu-clermontferrand.fr
Beguin, Yves ; Université de Liège - ULiège > Département des sciences cliniques
Bigenwald, Camille; Département d'hématologie, Gustave-Roussy, université Paris Saclay, Villejuif, France. Electronic address: CAMILLE.BIGENWALD@gustaveroussy.fr
Brissot, Eolia; Service d'hématologie et de thérapie cellulaire, hôpital Saint-Antoine, AP-HP Sorbonne université, 184, Faubourg-Saint-Antoine, 75012 Paris, France. Electronic address: eolia.brissot@aphp.fr
Chalandon, Yves; Service d'hématologie, département d'oncologie, hôpitaux universitaire Genève (HUG) et faculté de médecine, université de Genève, Genève, Suisse. Electronic address: Yves.Chalandon@hcuge.ch
Chevallier, Patrice; Hematology Department, Nantes University Hospital, Nantes, France. Electronic address: patrice.chevallier@chu-nantes.fr
Pagliuca, Simona; Service d'hématologie, UMR 7365, IMoPA, CNRS, campus Brabois Santé, hôpitaux de Brabois, CHRU de Nancy, université de Lorraine, Vandœuvre-lès-Nancy, France. Electronic address: smnpag@gmail.com
Magro, Léonardo; Maladies du sang, hôpital Huriez, CHRU de Lille, rue Michel-Polonowski, 59000 Lille, France. Electronic address: leonardo.magro@chu-lille.fr
Srour, Micha; Maladies du sang, hôpital Huriez, CHRU de Lille, rue Michel-Polonowski, 59000 Lille, France. Electronic address: micha.srour@chu-lille.fr
Language :
French
Title :
Toxicités hématologiques après CAR-T cells, recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC).
Alternative titles :
[en] Hematological toxicities post-CAR-T cells: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
Locke, F.L., Miklos, D.B., Jacobson, C.A., Perales, M.A., Kersten, M.J., Oluwole, O.O., et al. Axicabtagene ciloleucel as second-line therapy for large B-Cell lymphoma. N Engl J Med 386:7 (2022), 640–654.
Fowler, N.H., Dickinson, M., Dreyling, M., Martinez-Lopez, J., Kolstad, A., Butler, J., et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 28:2 (2022), 325–332.
Kamdar, M., Solomon, S.R., Arnason, J., Johnston, P.B., Glass, B., Bachanova, V., et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399:10343 (2022), 2294–2308.
Shah, B.D., Ghobadi, A., Oluwole, O.O., Logan, A.C., Boissel, N., Cassaday, R.D., et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 398:10299 (2021), 491–502.
Delforge, M., Baz, R.C., Cavo, M., Callander, N.S., Ghobadi, A., Rodriguez-Otero, P., et al. KarMMa-3: a phase 3 study of idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy vs standard regimens in relapsed and refractory multiple myeloma. Blood 136:Supplement 1 (2020), 24–25.
Mackensen, A., Müller, F., Mougiakakos, D., Böltz, S., Wilhelm, A., Aigner, M., et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 28:10 (2022), 2124–2132.
Hayden, P.J., Roddie, C., Bader, P., Basak, G.W., Bonig, H., Bonini, C., et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol 33:3 (2022), 259–275.
Mohty, M., Dulery, R., Gauthier, J., Malard, F., Brissot, E., Aljurf, M., et al. CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. Bone Marrow Transplant 55:8 (2020), 1525–1532.
Daei Sorkhabi, A., Mohamed Khosroshahi, L., Sarkesh, A., Mardi, A., Aghebati-Maleki, A., Aghebati-Maleki, L., et al. The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies. Front Immunol, 14, 2023, 1113882.
Shouse, G., Danilov, A.V., Artz, A., CAR T-cell therapy in the older person: indications and risks. Curr Oncol Rep 24:9 (2022), 1189–1199.
Larson, R.C., Maus, M.V., Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer 21:3 (2021), 145–161.
Luo, W., Li, C., Zhang, Y., Du, M., Kou, H., Lu, C., et al. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and meta-analysis. BMC Cancer, 22(1), 2022, 98.
Rejeski, K., Subklewe, M., Aljurf, M., Bachy, E., Balduzzi, A., Barba, P., et al. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood 142:10 (2023), 865–877.
Rejeski, K., Wu, Z., Blumenberg, V., Kunz, W.G., Müller, S., Kajigaya, S., et al. Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL. Blood 140:20 (2022), 2175–2179.
Rejeski, K., Perez, A., Iacoboni, G., Blumenberg, V., Bücklein, V.L., Völkl, S., et al. Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Sci Adv, 9(38), 2023, eadg3919.
Rejeski, K., Greco, R., Onida, F., Sánchez-Ortega, I., Bonini, C., Sureda, A., et al. An international survey on grading, diagnosis, and management of immune effector cell-associated hematotoxicity (ICAHT) following CAR T-cell therapy on behalf of the EBMT and EHA. Hemasphere, 7(5), 2023, e889.
Rejeski, K., Perez, A., Iacoboni, G., Penack, O., Bücklein, V., Jentzsch, L., et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. J Immunother Cancer, 10(5), 2022, e004475.
Rejeski, K., Perez, A., Sesques, P., Hoster, E., Berger, C., Jentzsch, L., et al. CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood 138:24 (2021), 2499–2513.
Tipton, R., Yakoub-Agha, I., Ateliers d'harmonisation des pratiques de la SFGM-TC. Bull Cancer 103:11 (2016), S193–S197.
Jain, T., Olson, T.S., Locke, F.L., How i treat cytopenias after CAR T-cell therapy. Blood 141:20 (2023), 2460–2469, 10.1182/blood.2022017415 [PMID: 36800563; PMCID: PMC10646792].
Kitamura, W., Asada, N., Naoi, Y., Abe, M., Fujiwara, H., Ennishi, D., et al. Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T-cell therapy. Br J Haematol 202:2 (2023), 294–307.
Read, J.A., Rouce, R.H., Mo, F., Mamonkin, M., King, K.Y., Apoptosis of hematopoietic stem cells contributes to bone marrow suppression following chimeric antigen receptor T cell therapy. Transplant Cell Ther, 29(3), 2023 [165.e1–165.e7].
Juluri, K.R., Wu, Q.V., Voutsinas, J., Hou, J., Hirayama, A.V., Mullane, E., et al. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Adv 6:7 (2022), 2055–2068.
Freites-Martinez, A., Santana, N., Arias-Santiago, S., Viera, A., Using the common terminology criteria for adverse events (CTCAE – version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 112:1 (2021), 90–92.
Paul, F., Vicente, C., Courbon, C., Moreau, A.S., Picard, M., Pochon, C., et al. Prise en charge prophylactique, thérapeutique des complications infectieuses et vaccination des patients traités par CAR-T cells : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bull Cancer 108:12 (2021), S90–S97.
Greenbaum, U., Strati, P., Saliba, R.M., Torres, J., Rondon, G., Nieto, Y., et al. CRP and ferritin in addition to the EASIX score predict CAR-T – related toxicity. Blood Adv 5:14 (2021), 2799–2806.
Kennedy, V.E., Wong, C., Huang, C.Y., Kambhampati, S., Wolf, J., Martin, T.G., et al. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv 5:23 (2021), 5344–5348.
Fried, S., Avigdor, A., Bielorai, B., Meir, A., Besser, M.J., Schachter, J., et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant 54:10 (2019), 1643–1650.
Roddie, C., Neill, L., Osborne, W., Iyengar, S., Tholouli, E., Irvine, D., et al. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Adv 7:12 (2023), 2872–2883.
Xia, Y., Zhang, J., Li, J., Zhang, L., Li, J., Fan, L., et al. Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors. Ann Med 54:1 (2022), 2951–2965.
Brudno, J.N., Kochenderfer, J.N., Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127:26 (2016), 3321–3330.
Alsuliman, T., Drieu La Rochelle, L., Campidelli, A., Duléry, R., Fayard, A., Mamez, A.C., et al. Suivi au moyen-terme des patients faisant l'objet d'un traitement par CAR-T cells : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bull Cancer 108:12 (2021), S65–S71.
Kampouri, E., Little, J.S., Rejeski, K., Manuel, O., Hammond, S.P., Hill, J.A., Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies. Transplant Infect Dis, 25(1), 2023, e14157, 10.1111/tid.14157 [Epub 2023 Oct 3. PMID: 37787373].
Stewart, A.G., Henden, A.S., Infectious complications of CAR T-cell therapy: a clinical update. Ther Adv Infect Dis, 8, 2021 [20499361211036773].
Reynolds, G., Sim, B., Anderson, M.A., Spelman, T., Teh, B.W., Slavin, M.A., et al. Predicting infections in patients with haematological malignancies treated with chimeric antigen receptor T-cell therapies: a systematic scoping review and narrative synthesis. Clin Microbiol Infect 29:10 (2023), 1280–1288.
Vic, S., Thibert, J.B., Bachy, E., Cartron, G., Gastinne, T., Morschhauser, F., et al. Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome. A DESCAR-T study. Blood Adv 8:6 (2024), 1573–1585, 10.1182/bloodadvances.2023011727 [PMID: 38181767; PMCID: PMC10982963].
Miller, P.G., Sperling, A.S., Brea, E.J., Leick, M.B., Fell, G.G., Jan, M., et al. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv 5:15 (2021), 2982–2986.
Caiado, F., Pietras, E.M., Manz, M.G., Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection. J Exp Med, 218(7), 2021, e20201541.
Lacout, C., Beucher, A.B., Ghali, A., Lavigne, C., Urbanski, G., Sensibilisation au syndrome d'activation macrophagique, l'expérience du service de médecine interne du CHU d'Angers. Rev Med Interne 37 (2016), A183–A184.
Brissot, E., Alsuliman, T., Gruson, B., Hermet, E., Tirefort, Y., Yakoub-Agha, I., et al. How to manage EBV reactivation and EBV-PTLD, CMV and human herpesvirus 6 reactivation and infection after allogeneic stem cell transplantation: a report of the SFGM-TC (update). Bull Cancer 104:12S (2017), S181–S187.
Brissot, E., Alsuliman, T., Beauvais, D., Bonnin, A., Mear, J.B., Souchet, L., et al. Prophylaxie antivirale pour le CMV, l'HSV/VZV et le VHB après allogreffe de cellules souches hématopoïétiques chez l'adulte : recommandations de la Société francophone de greffe de mœlle et de thérapie cellulaire (SFGM-TC). Bull Cancer 107:1 (2020), S1–S6.
Moulinet, T., Moussu, A., Pierson, L., Pagliuca, S., The many facets of immune-mediated thrombocytopenia: principles of immunobiology and immunotherapy. Blood Rev, 63, 2024, 101141.
Olnes, M.J., Scheinberg, P., Calvo, K.R., Desmond, R., Tang, Y., Dumitriu, B., et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 367:1 (2012), 11–19.
Guan, Y., Hasipek, M., Jiang, D., Tiwari, A.D., Grabowski, D.R., Pagliuca, S., et al. Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia. J Clin Invest, 132(4), 2022, e149856.
Alvarado, L.J., Huntsman, H.D., Cheng, H., Townsley, D.M., Winkler, T., Feng, X., et al. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ. Blood 133:19 (2019), 2043–2055.
Peffault De Latour, R., Chevret, S., Ruggeri, A.L., Suarez, F., Souchet, L., Michonneau, D., et al. Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial. Blood 135:3 (2020), 227–229.
Mahat, U., Rotz, S.J., Hanna, R., Use of thrombopoietin receptor agonists in prolonged thrombocytopenia after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 26:3 (2020), e65–e73.
Maximova, N., Zanon, D., Rovere, F., Maestro, A., Schillani, G., Paparazzo, R., Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children. Int J Hematol 102:5 (2015), 626–632.
Davis, J.A., Sborov, D.W., Wesson, W., Julian, K., Abdallah, A.O., McGuirk, J.P., et al. Efficacy and safety of CD34+ stem cell boost for delayed hematopoietic recovery after BCMA directed CAR T-cell therapy. Transplant Cell Ther 29:9 (2023), 567–571.
Gagelmann, N., Wulf, G.G., Duell, J., Glass, B., van Heteren, P., von Tresckow, B., et al. Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study. Blood Adv 7:4 (2023), 555–559.
